Journal: Human Brain Mapping

Article Title: Epigenetic variation in the serotonin transporter gene predicts resting state functional connectivity strength within the salience‐network

doi: 10.1002/hbm.22923

Figure Lengend Snippet: Positive correlations between amygdala resting state connectivity values and SLC6A4 methylation. A: Correlations between amygdala seed‐to‐voxel connectivity values and SLC6A4 methylation. Clusters are presented on a superior view of a glas brain build with conn toolbox (upper figure) and on axial and coronar slices of an anatomically averaged image of all participants build with SPM 12 (middle and lower figure). Results are presented on a voxel‐level of P < 0.001, FWE cluster corrected for multiple comparisons (P < 0.05). B: Scatter plots for visual inspection illustrate results from subsequent extracted mean connectivity values (ROI‐to‐ROI analyses): v/dACC = ventral/dorsal anterior cingulate cortices, AI = anterior insulae. [Color figure can be viewed in the online issue, which is available at http://wileyonlinelibrary.com.]

Article Snippet: Quantitative methylation at 83 CpG sites within a 799‐bp promoter‐associated CpG island of SLC6A4 initially described by Philibert et al. [ 2007 ] was performed by Varionostic GmbH (Ulm, Germany, http://www.varionostic.de ).

Techniques: Methylation

Journal: Human Brain Mapping

Article Title: Epigenetic variation in the serotonin transporter gene predicts resting state functional connectivity strength within the salience‐network

doi: 10.1002/hbm.22923

Figure Lengend Snippet: Peak voxels and cluster sizes derived from correlation analyses of amygdala seed‐to‐voxel connectivity and SLC6A4 methylation

Article Snippet: Quantitative methylation at 83 CpG sites within a 799‐bp promoter‐associated CpG island of SLC6A4 initially described by Philibert et al. [ 2007 ] was performed by Varionostic GmbH (Ulm, Germany, http://www.varionostic.de ).

Techniques: Derivative Assay, Methylation

Journal: Molecular Oncology

Article Title: Biomarker potential of ST 6 GALNAC 3 and ZNF 660 promoter hypermethylation in prostate cancer tissue and liquid biopsies

doi: 10.1002/1878-0261.12183

Figure Lengend Snippet: Promoter methylation and RNA expression of ST 6 GALNAC 3 and ZNF 660 in prostate tissue samples. (A, B) ST 6 GALNAC 3 and ZNF 660 qMSP data for samples of adjacent normal ( AN ), benign prostatic hyperplasia ( BPH ), prostatic intraepithelial neoplasia ( PIN ), localized prostate cancer from radical prostatectomies ( PC , RP cohort 1), primary tumors from metastatic PC ( MPC ), and primary tumors from castrate‐resistant PC ( CRPC ). ** P < 0.001, * P < 0.05 compared to PC samples. Gray lines: median methylation. P ‐values from Mann–Whitney U ‐tests. (C–J) Receiver operating characteristic ( ROC ) analysis comparing promoter methylation in nonmalignant and malignant tissue samples assayed by qMSP (C–D) or Illumina 450K DNA methylation array (E–J). 450K probes cg21526205 and cg22598028 for ST 6 GALNAC 3 and ZNF 660 , respectively, are shown. (C, D) 28 benign (16 AN and 12 BPH ) versus 169 RP samples. (E, F) 11 AN versus 19 PC . (G, H) 21 benign (9 N and 12 AN ) versus 20 PC . (I, J) 50 AN versus 497 PC . (K, L) mRNA expression in the TCGA cohort, 52 AN and 495 PC . (M, N) Correlation between promoter methylation and mRNA expression. In TCGA samples, 35 AN (gray dots) and 494 PC (black dots), Spearman correlation rho and P ‐values are given.

Article Snippet: Radical prostatectomy cohort 1 consisted of 234 consecutive curatively intended RPs of histologically verified, clinically localized PC from patients treated at Department of Urology, Aarhus University Hospital, from 1997 to 2005 and was used for DNA methylation analysis by quantitative methylation‐specific PCR (qMSP), as previously described (Haldrup et al ., ; Heeboll et al ., ).

Techniques: Methylation, RNA Expression, MANN-WHITNEY, DNA Methylation Assay, Expressing

Journal: Molecular Oncology

Article Title: Biomarker potential of ST 6 GALNAC 3 and ZNF 660 promoter hypermethylation in prostate cancer tissue and liquid biopsies

doi: 10.1002/1878-0261.12183

Figure Lengend Snippet: Kaplan–Meier plots. (A, B) ST 6 GALNAC 3 and ZNF 660 promoter methylation assayed by qMSP in RP cohort 1 divided into high and low methylation at the median; endpoint: biochemical recurrence after radical prostatectomy. (C, D) ST 6 GALNAC 3 and ZNF 660 promoter methylation assayed by 450K array in the TCGA cohort, samples divided into high and low methylation at the median; endpoint: biochemical recurrence after radical prostatectomy. (E, F) ZNF 660 promoter methylation in patients with Gleason score ≤7 in RP cohort 1 and the TCGA cohort. (G) ZNF 660 promoter methylation, dichotomized at top 5% most methylated; endpoint: overall survival. (H) ZNF 660 promoter methylation, dichotomized at top 5% most methylated; endpoint: PC ‐specific survival. P ‐values from log‐rank tests.

Article Snippet: Radical prostatectomy cohort 1 consisted of 234 consecutive curatively intended RPs of histologically verified, clinically localized PC from patients treated at Department of Urology, Aarhus University Hospital, from 1997 to 2005 and was used for DNA methylation analysis by quantitative methylation‐specific PCR (qMSP), as previously described (Haldrup et al ., ; Heeboll et al ., ).

Techniques: Methylation

Journal: Molecular Oncology

Article Title: Biomarker potential of ST 6 GALNAC 3 and ZNF 660 promoter hypermethylation in prostate cancer tissue and liquid biopsies

doi: 10.1002/1878-0261.12183

Figure Lengend Snippet: Clinicopathological characteristics of patients used for qMSP analyses of ST6GALNAC3 and ZNF660 promoter regions

Article Snippet: Radical prostatectomy cohort 1 consisted of 234 consecutive curatively intended RPs of histologically verified, clinically localized PC from patients treated at Department of Urology, Aarhus University Hospital, from 1997 to 2005 and was used for DNA methylation analysis by quantitative methylation‐specific PCR (qMSP), as previously described (Haldrup et al ., ; Heeboll et al ., ).

Techniques: